Abstract
Neuroendocrine tumors (NET) are a rare and heterogeneous group of tumors that represent a wide variety of clinical problems leading to many challenges for the clinician, including several emergencies. In this chapter, we will detail on selection of relevant emergencies that occur as complications of NETs. We will focus on the following topics: carcinoid syndrome, carcinoid crisis, and preoperative, intraoperative, and postoperative management to prevent a carcinoid crisis, carcinoid heart disease, approach of MEN-1, insulinoma, and VIPoma, and at least the challenge of a pheochromocytoma.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Melnyk DL (1997) Update on carcinoid syndrome. AANA J 65(3):265–270
Kulke MH, Mayer RJ (1999) Carcinoid tumors. N Engl J Med 340(11):858–868
Modlin IM, Sandor A (1997) An analysis of 8,305 cases of carcinoid tumors. Cancer 79(4):813–829
Van der Lely AJ, de Herder WW (2005) Carcinoid syndrome: diagnosis and medical management. Arq Bras Endocrinol Metabol 49(5):850–860
Vaughan DJ, Brunner MD (1997) Anesthesia for patients with carcinoid syndrome. Int Anesthesiol Clin 35(4):129–142
Mancuso K, Kaye AD, Boudreaux JP et al (2011) Carcinoid syndrome and perioperative anesthetic considerations. J Clin Anesth 23(4):329–341
Appetecchia M, Baldelli R (2010) Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res 29:19
Ramage JK, Ahmed A, Ardill J et al (2012) Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 61(1):6–32
Kahil ME, Brown H, Fred HL (1964) The carcinoid crisis. Arch Intern Med 114:26–28
Kinney MA, Warner ME, Nagorney DM et al (2001) Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours. Br J Anaesth 87(3):447–452
Furse RM, Green CJ, Mee AS (2008) Carcinoid syndrome unmasked by fluoxetine, a selective serotonin reuptake inhibitor. Clin Gastroenterol Hepatol 6(8):e27–e28
Claure RE, Drover DD, Haddow GR, Esquivel CO, Angst MS (2000) Orthotopic liver transplantation for carcinoid tumour metastatic to the liver: anesthetic management. Can J Anaesth 47(4):334–337
Camilleri M, Bueno L, de Ponti F, Fioramonti J, Lydiard RB, Tack J (2006) Pharmacological and pharmacokinetic aspects of functional gastrointestinal disorders. Gastroenterology 130(5):1421–1434
Beattie DT, Smith JA (2008) Serotonin pharmacology in the gastrointestinal tract: a review. Naunyn Schmiedebergs Arch Pharmacol 377(3):181–203
Pavel M, Baudin E, Couvelard A et al (2012) ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95(2):157–176
De Herder WW, Lamberts SW (2002) Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Curr Opin Oncol 14(1):53–57
Bauer W, Briner U, Doepfner W et al (1982) SMS 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31(11):1133–1140
Gupta S, Engstrom PF, Cohen SJ (2011) Emerging therapies for advanced gastroenteropancreatic neuroendocrine tumors. Clin Colorectal Cancer 10(4):298–309
Roy RC, Carter RF, Wright PD (1987) Somatostatin, anaesthesia, and the carcinoid syndrome. Peri-operative administration of a somatostatin analogue to suppress carcinoid tumour activity. Anaesthesia 42(6):627–632
Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK (1998) Carcinoid tumour. Lancet 352(9130):799–805
Rinke A, Müller HH, Schade-Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27(28):4656–4663
Öberg KE (2010) Gastrointestinal neuroendocrine tumors. Ann Oncol 21(Suppl 7):vii72–vii80
Salazar R, Wiedenmann B, Rindi G, Ruszniewski P (2012) ENETS 2011 consensus guidelines for the management of patients with digestive neuroendocrine tumors: an update. Neuroendocrinology 95(2):71–73
Wymenga AN, de Vries EG, Leijsma MK, Kema IP, Kleibeuker JH (1998) Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome. Eur J Cancer 34(8):1293–1294
Westergaard H (2007) Bile Acid malabsorption. Curr Treat Options Gastroenterol 10(1):28–33
Pratila MG, Pratilas V (1991) Propofol infusion in carcinoid syndrome. Can J Anaesth 38(7):943–944
Harris CE, Murray AM, Anderson JM, Grounds RM, Morgan M (1988) Effects of thiopentone, etomidate and propofol on the haemodynamic response to tracheal intubation. Anaesthesia 43(Suppl):32–36
Naguib M, Magboul MM (1998) Adverse effects of neuromuscular blockers and their antagonists. Middle East J Anesthesiol 14(5):341–373
Pellikka PA, Tajik AJ, Khandheria BK et al (1993) Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation 87(4):1188–1196
Zuetenhorst JM, Taal BG (2003) Carcinoid heart disease. N Engl J Med 348(23):2359–2361 author reply 2359–2361
Lundin L (1991) Carcinoid heart disease. A cardiologist’s viewpoint. Acta Oncol 30(4):499–502
Lundin L, Norheim I, Landelius J, Oberg K, Theodorsson-Norheim E (1988) Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation 77(2):264–269
Dumoulein M, Verslype C, Van Cutsem E et al (2010) Carcinoid heart disease: case and literature review. Acta Cardiol 65(2):261–264
Dero I, De Pauw M, Borbath I et al (2009) Carcinoid heart disease: a hidden complication of neuroendocrine tumours. Acta Gastroenterol Belg 72(1):34–38
Zuetenhorst JM, Bonfrer JM, Korse CM, Bakker R, Van Tinteren H, Taal BG (2003) Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor. Cancer 97(7):1609–1615
Piecha G, Chudek J, Więcek A (2010) Primary hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Int J Endocrinol 2010:928383
Milan SA, Yeo CJ (2012) Neuroendocrine tumors of the pancreas. Curr Opin Oncol 24(1):46–55
Whipple AO, Frantz VK (1935) Adenoma of islets cells with hyperinsulinism: a review. Ann Surg 101(6):1299–1335
Jensen RT, Cadiot G, Brandi ML et al (2012) ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 95(2):98–119
Service FJ (1995) Hypoglycemic disorders. N Engl J Med 332(17):1144–1152
Lairmore TC, Moley JF (2004) Endocrine pancreatic tumors. Scand J Surg 93(4):311–315
Tutt GO, Edis AJ, Service FJ, van Heerden JA (1980) Plasma glucose monitoring during operation for insulinoma: a critical reappraisal. Surgery 88(3):351–356
Chen H, Sippel RS, O’Dorisio MS et al (2010) The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 39(6):775–783
Pacak K (2007) Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab 92(11):4069–4079
Kantorovich V, Eisenhofer G, Pacak K (2008) Pheochromocytoma: an endocrine stress mimicking disorder. Ann N Y Acad Sci 1148:462–468
Baumann BM, Cline DM, Pimenta E (2011) Treatment of hypertension in the emergency department. J Am Soc Hypertens 5(5):366–377
Chang BB, Phan AT, Yao JC (2006) Neuroendocrine carcinoma. In: Wolff RA, Koller CA, Katarjian HM (eds) The M.D. Anderson manual of medical oncology. McGraw-Hill, New York, pp 449–460
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag France
About this chapter
Cite this chapter
Mertens, G., Carton, S., Verslype, C., Van Cutsem, E. (2014). Clinical Approaches of Emergencies in Neuroendocrine Tumors. In: Raymond, E., Faivre, S., Ruszniewski, P. (eds) Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract. Springer, Paris. https://doi.org/10.1007/978-2-8178-0430-9_15
Download citation
DOI: https://doi.org/10.1007/978-2-8178-0430-9_15
Published:
Publisher Name: Springer, Paris
Print ISBN: 978-2-8178-0429-3
Online ISBN: 978-2-8178-0430-9
eBook Packages: MedicineMedicine (R0)